Belite Bio, a subsidiary of Lin BioScience, is a San Diego-based biopharma venture targeting untreatable diseases such as age-related macular degeneration, Stargardt disease, and liver diseases.
The industry sponsor has received U.S. Food and Drug Administration (FDA) Investigatory New Drug (IND) approval for its LBS-008 (BPN-14967), a first-in-class oral therapy for the treatment of atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease, an inherited juvenile form of macular degeneration.
The LBS-008 intellectual property originates from the U.S. National Institute of Health’s (NIH) Blueprint Neurotherapeutics Network (Blueprint Program), which was funded LBS-008’s discovery and development—and interestingly, will continue to provide support and funding until completion of Phase I single ascending dose (SAD) clinical trial.
The technology underlying LBS-008 was invested by Dr. Konstantin Petrukhin, Associate Professor of Ophthalmic Science at Columbia University Medical Center. It is hoped that if successful in the clinical trials process it will bring hope to millions of macular degeneration patients.
Belite Bio holds the worldwide...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).